Nov 06, 2024 7:00am EST Immunocore reports third quarter financial results and provides a business update
Sep 14, 2024 3:00am EDT Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
Aug 08, 2024 7:00am EDT Immunocore reports second quarter financial results and provides a business update
Aug 01, 2024 7:00am EDT Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
Jun 18, 2024 7:00am EDT Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
Jun 01, 2024 8:00am EDT Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
May 31, 2024 4:05pm EDT Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024